SDSonglin Du

Songlin Du

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Songlin Du has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • De-Shen Liu

    Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

    1 shared publication
  • Dongtu Hu

    State Key Laboratory of Multi-Organ Injury Prevention and Treatment, National Clinical Research Center for Kidney and Urological Diseases, Department of Cardiology, Nanfang Hospital, Southern Medical University, 510515, Guangzhou, China (D.H., Y.L., H.H., G.X., J.L., L.H., M.X., X.L., L.W., S.S., X.D., G.Z., Q.Z.).

    1 shared publication
  • Fang-Ze Huang

    Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

    1 shared publication
  • Gaopeng Xian

    State Key Laboratory of Multi-Organ Injury Prevention and Treatment, National Clinical Research Center for Kidney and Urological Diseases, Department of Cardiology, Nanfang Hospital, Southern Medical University, 510515, Guangzhou, China (D.H., Y.L., H.H., G.X., J.L., L.H., M.X., X.L., L.W., S.S., X.D., G.Z., Q.Z.).

    1 shared publication
  • Guoheng Zhong

    State Key Laboratory of Multi-Organ Injury Prevention and Treatment, National Clinical Research Center for Kidney and Urological Diseases, Department of Cardiology, Nanfang Hospital, Southern Medical University, 510515, Guangzhou, China (D.H., Y.L., H.H., G.X., J.L., L.H., M.X., X.L., L.W., S.S., X.D., G.Z., Q.Z.).

    1 shared publication
  • Hailun Huang

    State Key Laboratory of Multi-Organ Injury Prevention and Treatment, National Clinical Research Center for Kidney and Urological Diseases, Department of Cardiology, Nanfang Hospital, Southern Medical University, 510515, Guangzhou, China (D.H., Y.L., H.H., G.X., J.L., L.H., M.X., X.L., L.W., S.S., X.D., G.Z., Q.Z.).

    1 shared publication

Latest Publications

  • CircZBTB44-Encoded Peptide ZBTB44-342aa Alleviates Aortic Valve Calcification Via cGAS-STING Inhibition

    by Dongtu Hu, Yingwen Lin, Hailun Huang, Gaopeng Xian, Yubing Chen, Juncong Li, Lin Huang, Minhui Xu, Xiangjie Lin, Liming Wen, et al.

    BACKGROUND: Circular RNAs are implicated in various physiopathologic activities and play a crucial role in calcific aortic valve disease (CAVD) progression. However, the role of coding circular RNAs in CAVD remains unclear. In this study, we aimed to characterize coding circular RNAs and explore their functions in CAVD. METHODS: Using a systematic approach from transcriptome sequencing to experimental validation, we identified circZBTB44, confirmed its translation into ZBTB44-342aa, and investigated the function and mechanism of this peptide in CAVD using both cellular and animal models. RESULTS: We found that circZBTB44 promotes the translation of ZBTB44-342aa through N6-methyladenosine modifications. Functionally, ZBTB44-342aa binds to IGF2BP3 (insulin-like growth factor 2 mRNA-binding protein 3), which inhibits mitochondrial damage and mtDNA release into the cytoplasm, thereby suppressing the activation of the cGAS-STING (stimulator of interferon genes) pathway and alleviating the osteogenic differentiation of human aortic valve interstitial cells. Consistent with this, both circZBTB44 overexpression and STING deprivation alleviated aortic valve lesions in vivo, while in vitro, overexpressing circZBTB44 or adding ZBTB44-342aa recombinant protein inhibited the osteogenic response. Conversely, siRNA-mediated knockdown of circZBTB44 enhanced this response. Furthermore, STING inhibition by H-151 alleviated the osteogenic response, whereas its activation by dimeric amidobenzimidazole exacerbated it. CONCLUSIONS: This study demonstrates that circZBTB44-encoded ZBTB44-342aa alleviates CAVD progression by inhibiting the cGAS-STING signaling pathway, thereby identifying both circZBTB44 and STING as potential therapeutic targets.


  • Macrophage KLF15 prevents foam cell formation and atherosclerosis via transcriptional suppression of OLR-1

    by Zheng-Kun Song, Li Zhao, De-Shen Liu, Ling-Na Zhao, Qin-Bao Peng, Zi-Yao Li, Jia-Yong Wu, Si-Kai Chen, Fang-Ze Huang, Xing Chen, et al.


  • Open Access

    Protective Effects of MicroRNA‐200b‐3p Encapsulated by Mesenchymal Stem Cells–Secreted Extracellular Vesicles in Myocardial Infarction Via Regulating BCL2L11

    by Jun Wan, Shaoyan Lin, Zhuo Yu, Zhengkun Song, Xuefeng Lin, Rongning Xu, Songlin Du

    Background: Extracellular vesicles (EVs) are a popular treatment candidate for myocardial injury. This work investigated the effects of mesenchymal stem cells (MSCs)–secreted EVs–derived miR‐200b‐3p on cardiomyocyte apoptosis and inflammatory response after myocardial infarction (MI) through targeting BCL2L11 (Bcl‐2–like protein 11) . Methods and Results: EVs from MSCs were isolated and identified. EVs from MSCs with transfection of miR‐200b‐3p for overexpression were injected into MI mice. The effect of miR‐200b‐3p on cardiac function, infarction area, myocardial fibrosis, cardiomyocyte apoptosis, and inflammatory response was determined in MI mice. The targeting relationship between miR‐200b‐3p and BCL2L11 was verified, and the interaction between BCL2L11 and NLR family pyrin domain containing 1 (NLRP1) was also verified. MI mice were injected with an overexpressing BCL2L11 lentiviral vector to clarify whether BCL2L11 can regulate the effect of miR‐200b‐3p on MI mice. EVs from MSCs were successfully extracted. MSCs‐EVs improved cardiac function and reduced infarction area, apoptosis of cardiomyocytes, myocardial fibrosis, and inflammation in MI mice. Upregulation of miR‐200b‐3p further enhanced the effects of MSCs‐EVs on the myocardial injury of MI mice. BCL2L11 was targeted by miR‐200b‐3p and bound to NLRP1. Upregulation of BCL2L11 negated the role of miR‐200b‐3p–modified MSCs‐EVs in MI mice. Conclusions: A summary was obtained that miR‐200b‐3p–encapsulated MSCs‐EVs protect against MI‐induced apoptosis of cardiomyocytes and inflammation via suppressing BCL2L11.